The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

Summary: Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma and one of the most challenging blood cancers to combat due to frequent relapse after treatment. Here, we developed the first-in-class BTK/PI3K/BRD4 axis inhibitor SRX3262, which simultaneously blocks three i...

Full description

Bibliographic Details
Main Authors: Dhananjaya Pal, Kendra R. Vann, Shweta Joshi, Namood E. Sahar, Guillermo A. Morales, Dalia El-Gamal, Tatiana G. Kutateladze, Donald L. Durden
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:iScience
Subjects:
Medical Biochemistry
Molecular Physiology
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221008993

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221008993

Similar Items